IGC Pharma, Inc. (FRA:IGS1)
Germany · Delayed Price · Currency is EUR 0.2740
0.00 (0.00%)
At close: Nov 28, 2025
IGC Pharma Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 1.11 | 1.27 | 1.35 | 0.91 | 0.4 | 0.9 | Upgrade | |
Revenue Growth (YoY) | -6.51% | -5.50% | 47.64% | 129.47% | -55.79% | -77.95% | Upgrade |
Cost of Revenue | 0.6 | 0.65 | 0.61 | 0.47 | 0.2 | 0.79 | Upgrade |
Gross Profit | 0.51 | 0.62 | 0.73 | 0.44 | 0.19 | 0.11 | Upgrade |
Selling, General & Admin | 4.32 | 4.41 | 6.76 | 8.55 | 12.46 | 7.91 | Upgrade |
Research & Development | 4.29 | 3.66 | 3.77 | 3.46 | 2.33 | 0.93 | Upgrade |
Operating Expenses | 8.61 | 8.07 | 10.53 | 12.01 | 14.79 | 8.84 | Upgrade |
Operating Income | -8.1 | -7.45 | -9.8 | -11.57 | -14.6 | -8.72 | Upgrade |
Other Non Operating Income (Expenses) | 1.62 | 0.3 | 0.1 | 0.1 | 0.03 | 0.08 | Upgrade |
EBT Excluding Unusual Items | -6.47 | -7.15 | -9.7 | -11.47 | -14.56 | -8.64 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.05 | -0.17 | Upgrade |
Gain (Loss) on Sale of Assets | 0.03 | 0.03 | 0.04 | -0.04 | - | - | Upgrade |
Asset Writedown | 0 | - | -3.35 | - | -0.83 | - | Upgrade |
Other Unusual Items | - | - | - | - | 0.43 | - | Upgrade |
Pretax Income | -6.45 | -7.12 | -13 | -11.51 | -15.02 | -8.81 | Upgrade |
Earnings From Continuing Operations | -6.45 | -7.12 | -13 | -11.51 | -15.02 | -8.81 | Upgrade |
Net Income | -6.45 | -7.12 | -13 | -11.51 | -15.02 | -8.81 | Upgrade |
Net Income to Common | -6.45 | -7.12 | -13 | -11.51 | -15.02 | -8.81 | Upgrade |
Shares Outstanding (Basic) | 83 | 77 | 59 | 53 | 50 | 42 | Upgrade |
Shares Outstanding (Diluted) | 83 | 77 | 59 | 53 | 50 | 42 | Upgrade |
Shares Change (YoY) | 19.49% | 30.04% | 11.91% | 5.17% | 19.13% | 6.26% | Upgrade |
EPS (Basic) | -0.08 | -0.09 | -0.22 | -0.22 | -0.30 | -0.21 | Upgrade |
EPS (Diluted) | -0.08 | -0.09 | -0.22 | -0.22 | -0.30 | -0.21 | Upgrade |
Free Cash Flow | -5.63 | -4.91 | -5.34 | -7.36 | -7.7 | -12.27 | Upgrade |
Free Cash Flow Per Share | -0.07 | -0.06 | -0.09 | -0.14 | -0.15 | -0.29 | Upgrade |
Gross Margin | 46.20% | 48.70% | 54.50% | 48.52% | 48.87% | 12.58% | Upgrade |
Operating Margin | -731.92% | -585.84% | -728.48% | -1270.14% | -3676.32% | -971.49% | Upgrade |
Profit Margin | -582.82% | -560.27% | -966.54% | -1263.01% | -3782.37% | -981.18% | Upgrade |
Free Cash Flow Margin | -508.68% | -386.07% | -396.80% | -807.57% | -1939.04% | -1366.37% | Upgrade |
EBITDA | -7.52 | -6.83 | -9.16 | -10.91 | -13.94 | -8.25 | Upgrade |
D&A For EBITDA | 0.57 | 0.62 | 0.64 | 0.66 | 0.65 | 0.48 | Upgrade |
EBIT | -8.1 | -7.45 | -9.8 | -11.57 | -14.6 | -8.72 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.